Canada seeks to curtail dispute options for drug companies
This article was originally published in SRA
Executive Summary
Health Canada is proposing to do away with its practice of allowing drug companies to dispute the decision it makes on applications that seek fast-track review of certain drugs for unmet patient needs1.